Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China NT Pharma Group Co., Ltd. ( (HK:1011) ) just unveiled an update.
China NT Pharma Group Company Limited has completed a major transaction to acquire 100% of the issued shares in three target companies, paying the consideration by issuing 274,751,679 new shares at HK$0.45 each to eight sellers. As a result, these targets have become indirect wholly owned subsidiaries, and China NT Pharma now indirectly holds a 58.11% equity stake in Zhejiang Kangyuan Medical Equipment, whose financial results will be consolidated into the group’s accounts.
The transaction significantly reshapes the company’s shareholding structure, increasing total issued shares from 674,246,015 to 948,997,694 and diluting existing major shareholders’ percentage holdings. Several new substantial shareholders, including individuals such as Lou YongBin, Lou YongJun, Chen HongLi and others, have emerged with notable stakes, potentially altering the balance of influence among stakeholders and signaling a strategic push into medical equipment for the group.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited is a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands, operating through a network of subsidiaries. The company focuses on healthcare-related businesses and has now expanded into the medical equipment segment through new indirect holdings in Zhejiang Kangyuan Medical Equipment Co., Ltd.
Average Trading Volume: 335,667
Technical Sentiment Signal: Hold
Current Market Cap: HK$485.5M
For detailed information about 1011 stock, go to TipRanks’ Stock Analysis page.